VALBIOTIS is a biopharmaceutical company distinguished by its unique approach to chronic metabolic disorders. Its proprietary R&D platform discovers and develops first-in-class patented polymolecular complexes indicated at specific stages in the progression of chronic illnesses such as type-2 diabetes, obesity, dyslipidemia or even NASH (Non-Alcoholic Steatotic Hepatitis). From the plant to the polymolecular complex, and from prevention to treatment, dedicated to people’s health and well-being.